BioCentury | Jan 25, 2019
Finance

Kurma’s Munich move

...Kurma’s Munich office, told BioCentury that Germany’s first generation of VCs poured money into the then-nascent biotech...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...cancer, no gene expression signatures were predictive of antitumor activity by Stivarga. 5036 / 11 Nascent Biotech Inc....
BioCentury | Apr 14, 2014
Finance

Guest Commentary: Reducing the burden of disclosure

...about a company. That may not always be true, particularly for smaller biotechs. For a nascent biotech...
Items per page:
1 - 3 of 3
BioCentury | Jan 25, 2019
Finance

Kurma’s Munich move

...Kurma’s Munich office, told BioCentury that Germany’s first generation of VCs poured money into the then-nascent biotech...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...cancer, no gene expression signatures were predictive of antitumor activity by Stivarga. 5036 / 11 Nascent Biotech Inc....
BioCentury | Apr 14, 2014
Finance

Guest Commentary: Reducing the burden of disclosure

...about a company. That may not always be true, particularly for smaller biotechs. For a nascent biotech...
Items per page:
1 - 3 of 3